Kalos Therapeutics Announces Important Progress In Covid-19 Preventative & Therapeutic Approaches

PHOENIX - April 9, 2020 - PRLog -- Kalos Therapeutics today announced the latest progress in its efforts to discover and develop a novel multi-drug cocktail of investigational peptide KTH-222 and immune-stimulating agents that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as a treatment for immune-compromised cancer patients already infected. The key here will be the ability to also treat asymptomatic patients. Kalos has identified numerous immune-stimulating agents and will target two based on safety and efficacy, as well as other desirable attributes, to begin development.
George Colberg, CEO of Kalos Therapeutics, said, "Through our network of patients and KOL's we are learning that many patients are reluctant to venture out for the continuation of therapies that may have weakened their immune system. Using a multi-drug approach to protect the most vulnerable cancer patients with cardiovascular issues and/or weakened immune system is an urgent unmet need that is a priority for Kalos Therapeutics."  He added, "KTH-222 as a monotherapy and/or in combination with FDA-approved anti-viral therapies or as compassionate drugs will potentially benefit cancer patients at risk including those not yet demonstrating symptoms."

In order to meet the pressing public health need, Kalos is utilizing BARDA resources to expedite funding through BAA and Corona Watch Meeting, collaborative opportunities, vet techniques, hone strategies, and align with Government priorities to address this unmet need.

Visit: https://kalostherapeutics.com/

ABOUT KALOS THERAPEUTICS, INC.

Kalos is pursuing a multi-phase strategy to reorient today's therapeutic approach to cancer patients while driving changes to transform therapeutic approaches for unmet and rare medical conditions. Kalos has a lead compound KTH 222, which is more promising than "standard of care" drugs with difficult to treat tumors.

        FORWARD-LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, the costs of providing funding to these business relationships. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.